HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New York's Prop 65-Like Proposal Dropped From Budget, But Talks Continue

Executive Summary

Governor Andrew Cuomo’s Consumer Right to Know Act, New York’s answer to Prop 65 in California, was scuttled by legislators in their budget bill signed into law April 12. However, related talks are ongoing in the state’s legislature, where the Safe Cosmetics Act is on the table again this session.

You may also be interested in...



New York Cosmetic Ingredient Bill Still In Committee With Clock Running Out

New York continues chasing California in its efforts to increase regulation of the cosmetic products sector.

Cosmetics Market In 2019: ‘Clean’ Beauty Picks Up Speed As Legislative Reform Efforts Chug Along

Cosmetics regulatory reform efforts continued in 2019, which also saw Congress’s first cosmetics safety hearing since 2016. Meanwhile, the “clean” beauty movement gained momentum, fueled by the widely held perception that outdated regulations are allowing cosmetics consumers to be exposed to dangerous chemicals.

Industry Presses NY Governor Not To Sign 1,4-Dioxane Bill, Warns Of Far-Reaching Consequences

Market disruptions, “dramatically” higher prices, lost jobs and negative health consequences all are possible if legislation passed in New York in June to reduce 1,4-dioxane exposures is enacted in its current form, trade organizations say. Cleaning product industry advocates are leading the opposition, but personal-care manufacturers stand to be impacted as well.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel